Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2003-03-21
2010-12-14
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S193100, C424S194100, C424S277100, C530S350000, C435S183000
Reexamination Certificate
active
07850971
ABSTRACT:
The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.
REFERENCES:
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5538866 (1996-07-01), Israeli et al.
patent: 5738867 (1998-04-01), Spitler
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5804602 (1998-09-01), Slusher et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5935818 (1999-08-01), Israeli et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6107090 (2000-08-01), Bander
patent: 6136311 (2000-10-01), Bander
patent: 6150508 (2000-11-01), Murphy et al.
patent: 6224870 (2001-05-01), Segal et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6387888 (2002-05-01), Mincheff et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6569432 (2003-05-01), Israeli et al.
patent: 6649163 (2003-11-01), Bander et al.
patent: 6770450 (2004-08-01), Bander et al.
patent: 6897062 (2005-05-01), Heston et al.
patent: 6953668 (2005-10-01), Israeli et al.
patent: 6962981 (2005-11-01), Murphy
patent: 7037647 (2006-05-01), Israeli et al.
patent: 7070782 (2006-07-01), Israeli et al.
patent: 7105159 (2006-09-01), Israeli et al.
patent: 7112412 (2006-09-01), Bander et al.
patent: 7163680 (2007-01-01), Bander et al.
patent: 7201900 (2007-04-01), Murphy et al.
patent: 7381407 (2008-06-01), Murphy et al.
patent: 7399461 (2008-07-01), Heston et al.
patent: 7476513 (2009-01-01), Murphy et al.
patent: 7514078 (2009-04-01), Bander et al.
patent: 7666425 (2010-02-01), Bander
patent: 2001/0036928 (2001-11-01), Chamberlain et al.
patent: 2002/0015704 (2002-02-01), Bander
patent: 2002/0155093 (2002-10-01), Houghton et al.
patent: 2002/0164318 (2002-11-01), Houghton et al.
patent: 2003/0003101 (2003-01-01), Bander
patent: 2003/0027246 (2003-02-01), Pedyczak et al.
patent: 2003/0031673 (2003-02-01), Bander
patent: 2003/0046714 (2003-03-01), Simard et al.
patent: 2003/0220239 (2003-11-01), Simard et al.
patent: 2004/0001846 (2004-01-01), Israeli et al.
patent: 2004/0024188 (2004-02-01), Murphy et al.
patent: 2004/0037843 (2004-02-01), Fikes et al.
patent: 2004/0105865 (2004-06-01), Bander
patent: 2004/0120958 (2004-06-01), Bander et al.
patent: 2004/0161776 (2004-08-01), Maddon et al.
patent: 2004/0180354 (2004-09-01), Simard et al.
patent: 2004/0198657 (2004-10-01), Heston et al.
patent: 2004/0253246 (2004-12-01), Israeli et al.
patent: 2005/0064504 (2005-03-01), Heston et al.
patent: 2005/0142144 (2005-06-01), Simard et al.
patent: 2005/0202020 (2005-09-01), Ross et al.
patent: 2005/0215472 (2005-09-01), Schulke et al.
patent: 2005/0260234 (2005-11-01), Simard et al.
patent: 2006/0024316 (2006-02-01), Spitler et al.
patent: 2006/0062793 (2006-03-01), Webb et al.
patent: 2006/0177450 (2006-08-01), Israeli et al.
patent: 2006/0234271 (2006-10-01), Su et al.
patent: 2006/0275212 (2006-12-01), Bander et al.
patent: 2007/0020278 (2007-01-01), Ross et al.
patent: 2007/0036719 (2007-02-01), Cuello et al.
patent: 2007/0128671 (2007-06-01), Murphy et al.
patent: 2007/0148662 (2007-06-01), Israeli et al.
patent: 2007/0160617 (2007-07-01), Ma et al.
patent: 2007/0254316 (2007-11-01), Rodriguez et al.
patent: 2008/0286284 (2008-11-01), Maddon et al.
patent: 2009/0238755 (2009-09-01), Bander
patent: 2009/0285843 (2009-11-01), Simard et al.
patent: 2009/0311225 (2009-12-01), Koduri
patent: 1 917 970 (2008-05-01), None
patent: WO 93/10763 (1993-06-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 96/26272 (1996-08-01), None
patent: WO 96/39185 (1996-12-01), None
patent: WO 97/35616 (1997-10-01), None
patent: WO 98/03873 (1998-01-01), None
patent: WO 99/47554 (1999-09-01), None
patent: WO 00/06723 (2000-02-01), None
patent: WO 00/18933 (2000-04-01), None
patent: WO 00/52156 (2000-09-01), None
patent: WO 00/61605 (2000-10-01), None
patent: WO 01/009192 (2001-02-01), None
patent: WO 01/74845 (2001-10-01), None
patent: WO 02/062368 (2002-08-01), None
patent: WO 02/069907 (2002-09-01), None
patent: WO 02/089747 (2002-11-01), None
patent: WO 03/023026 (2003-03-01), None
patent: WO 03/034903 (2003-05-01), None
patent: WO 03/040165 (2003-05-01), None
patent: WO 03/057921 (2003-07-01), None
patent: WO 03/064606 (2003-08-01), None
patent: WO 03/073828 (2003-09-01), None
patent: WO 2006/125481 (2006-11-01), None
Troyer et al. (Int. J. Cancer 1995; 62: 552-558).
Carter et al. (Proc. Natl. Acad. Sci. USA. Jan. 1996; 93: 749-753).
Schulke et al. (Proc. Natl. Acad. Sci. USA. Oct. 28, 2003; 100 (22): 12590-12595).
Mincheff et al. (Eur. Urol. Aug. 2000; 38 (2): 208-217).
Donovan et al., Antibody and vaccine therapies targeting prostate specific membrane antigen (PSMA). Proceedings of the Annual Meeting of the AACR. New York, NY. Mar. 24, 2001;42:818. Abstract 4389.
Gong et al., Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 1999;18 (4):483-90.
Holmes et al., PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs. Mar. 2001;10(3):511-9.
Lapidus et al., Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. Dec. 1, 2000;45(4):350-4.
Liu et al., Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. Sep. 1, 1997;57(17):3629-34.
Smith-Jones et al., In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. Sep. 15, 2000;60(18):5237-43.
Tino et al., Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma. Jun. 2000;19(3):249-57.
Barinka et al., Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem. Feb. 2002;80(3):477-87.
Ma et al., PSMA-targeted toxin- and radio-labelled antibody therapies for prostate cancer. J Urology. Apr. 2003;169(4):211. Poster 817.
Ma et al., Fully human anti-PSMA antibodies for prostate cancer therapy. Proceedings of the American Association for Cancer Research Annual Meeting. Jul. 2003;44:1295. Poster 6471.
Schülke et al., The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA. Oct. 28, 2003;100(22):12590-5.
Schülke et al., Human Prostate Specific Membrane Antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy. Eur J Cancer. Nov. 2002;38:S153. Poster 510.
Sokoloff et al., A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. May 1, 2000;43(2):150-7.
Speno et al., Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol. Jan. 1999;55(1):179-85.
Troyer et al., Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. Sep. 4, 1995;62(5):552-8.
Xiao et al., Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. Protein Expr Purif. Jun. 2000;19(1):12-21.
Ablin “Immunotherapy for prostatic cancer. Previous and Prospective Considerations1”,Oncology(1975) vol. 31, 177-202.
Alvarez et al., Intermolec
Donovan Gerald P.
Gardner Jason
Ma Dangshe
Maddon Paul J.
Olson William C.
PSMA Development Company, LLC
Rawlings Stephen L
Wolf Greenfield & Sacks P.C.
LandOfFree
PSMA antibodies and protein multimers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PSMA antibodies and protein multimers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PSMA antibodies and protein multimers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4164247